Market Access
Strengthen Your Reimbursement Pathway with a Strong Market Access Strategy
Securing reimbursement is as critical as demonstrating clinical efficacy. Thelansis works with biopharma clients to anticipate payer and HTA requirements, navigate access barriers, and build evidence-backed value strategies for global markets.
We assess your asset through the lenses of payer behaviour, budget impact, cost-effectiveness thresholds, and competitive pricing to help you prepare early for challenging reimbursement environments.
What We Do:
Through structured access research and payer evidence mapping, we identify the factors that will influence acceptance, pricing, and coverage decisions.
Our access support includes: Early payer value assessment (EPVA), Pricing and reimbursement landscape analysis, Identification of access barriers and cost-effectiveness challenges, Value proposition and value story development, Evidence generation planning for HTAs and payers, launch sequencing based on access probability.
A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence that their clinical evidence, pricing expectations, and value communication would withstand payer scrutiny. The therapy showed strong early promise, but the success in Phase 3 does not automatically translate into smooth reimbursement pathways, especially in regions where HTA bodies demand tight alignment between clinical value, real-world relevance, and economic justification.
Learn more: Strengthening Global Market Access Readiness Through Early Payer & HTA Planning
A biopharma company was preparing to launch a first-in-class therapy in immunology TA. The asset showed strong clinical promise, but its commercial team faced a familiar challenge: every market had different payer expectations, and a single misstep on price in one country could trigger ripple effects across the global reference pricing network.
We Provide Answers to Critical Questions:
Our insights help clients accelerate time-to-access, strengthen payer negotiations, and build a sustainable commercial pathway.
What will payers consider meaningful value in this indication?
Which markets offer the strongest likelihood of early access?
What evidence gaps may limit reimbursement or pricing power?
How should we position the asset against competitors to secure access?
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.